Moderna vs Regeneron Pharmaceuticals: why the prices moved differently

• ▲

  Nasdaq-100 inclusion to bring index-fund demand Moderna will join the Nasdaq-100 on October 9, replacing Warner Bros. Discovery. Index funds tracking the index, which has over $800 billion in assets, must buy the stock, creating a fresh wave of demand. This is a new event that can lift the share price in the near term.

  It is a new, concrete catalyst that directly affects demand for MRNA shares.

• ▲

  Cancer vaccine moves toward commercialization with Tempus deal Tempus will help Moderna and Merck collect tumor samples and handle the complex sequencing needed to make the personalized cancer vaccine intismeran autogene. This supports the path to selling the treatment, a potential multi-billion-dollar product. It is a new step that boosts confidence in future revenue.

  It is a new development that advances the cancer vaccine toward market, supporting the growth story.

• ▼

  Citi downgrade warns valuation is too high Citi downgraded Moderna to sell, saying the stock price cannot be justified after the cancer vaccine win. The analyst argues the market is pricing in far more sales and profit than Moderna is likely to deliver. This is a new warning that could pull the stock down as investors rethink the rally.

  It is a new analyst action that directly challenges the stock's valuation and can pressure the price.

• ▼

  Patent lawsuit over mRNA technology moves forward A Delaware judge refused to dismiss Monsanto's patent infringement lawsuit against Moderna over its COVID-19 vaccine. The case will now proceed, creating legal uncertainty and potential financial liability. This is a new legal setback that could weigh on the stock.

  It is a new legal development that introduces risk and uncertainty for MRNA.

Based on 14 stories →

• ▲

  FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.

  This is a new regulatory milestone that expands Moderna's commercial opportunity.

• ▲

  Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.

  This is a new pipeline advancement that broadens the platform's application.

• ▲

  Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.

  This is the core new event that re-rates Moderna's growth story.

• ▲

  Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.

  This shows the market's ongoing positive reaction to the cancer vaccine news.

Based on 6 stories →

• ▲

  FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.

  New regulatory approvals directly expand Moderna's product lineup and revenue potential.

• ▲

  GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.

  A rival's progress independently validates the mRNA platform Moderna is built on.

• ▲

  August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.

  Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

Based on 6 stories →

• ▲

  First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the single biggest new event of the period and the core reason MRNA moved.

• ▲

  Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.

  Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.

• ▼

  $2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.

  This is the main new negative force this period and explains why MRNA fell for three straight sessions.

• ◆

  BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.

  This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

Based on 23 stories →

• ▲

  First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.

• ▲

  Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.

  Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.

• ▼

  Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.

  The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.

• ◆

  Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.

  This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

Based on 20 stories →

• ▲

  FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.

  This is the biggest new event, directly adding a new product and validating the platform.

• ▼

  Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.

  This is a new negative event that offsets the flu approval and affects pipeline sentiment.

• ▲

  Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.

  This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.

• ▼

  Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.

  This is a new cash outflow event that affects Moderna's financial position.

Based on 6 stories →

• ▲

  Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.

  This is the main new financial event of the period and directly affects investor confidence in MRNA.

• ▲

  FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.

  This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.

• ▼

  Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.

  This is a new negative development that tempers the positive earnings news and highlights pipeline risk.

• ▲

  Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.

  This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

Based on 7 stories →

• ▲

  Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.

  New analyst and media endorsements directly lifted investor sentiment and the stock price.

• ▲

  Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.

  The Science Day event was a major catalyst that expanded the growth story and attracted investors.

• ▼

  Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.

  This is a new negative development that highlights a real risk to Moderna's core vaccine business.

• ▼

  Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.

  This new payment is a concrete financial hit and shows ongoing litigation costs.

Based on 6 stories →

• ▲

  Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.

  This is the main new event of the period and directly explains the stock's surge.

• ▲

  FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.

  This is a new regulatory milestone that de-risks a key product and supports the stock's rise.

• ▲

  Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.

  This new earnings data provides fundamental support for the stock's recent gains.

• ◆

  Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.

  This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

Based on 7 stories →

• ▲

  FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.

  This is the main new event that directly lifts MRNA's price by de-risking a major product approval.

• ▲

  Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.

  This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.

• ▼

  Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.

  This new settlement is a significant negative financial event that weighs on MRNA's price.

Based on 7 stories →

• ▲

  Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

  This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

• ▼

  Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

  These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

• ▼

  Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

  This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

• ▲

  Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

  This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

Based on 10 stories →

• ▲

  Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

  This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

• ▲

  Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

  A positive clinical readout in a major new market area is a key driver of future growth expectations.

• ▼

  Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

  Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

• ▲

  Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

  It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Based on 7 stories →

• ▲

  Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

  This is the period's biggest positive fundamental driver of REGN's value.

• ▲

  Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

  It is a concrete capital event that improves future profitability.

• ▲

  FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

  A new FDA approval is a fresh product and pipeline milestone for REGN.

• ▼

  Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

  This is the main negative overhang on REGN this period.

Based on 7 stories →

• ▲

  Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

  This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

• ▼

  Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

  This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

• ▼

  Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

  This new analyst commentary underscores pipeline challenges that could pressure the stock.

Based on 7 stories →

• ▲

  CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

  This is a new deal that adds to Regeneron's pipeline and potential future earnings.

• ▲

  Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

  Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

• ▲

  FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

  This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

• ▼

  AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

  This is a new competitive threat that could impact Regeneron's key product, Dupixent.

Based on 7 stories →